Verwendungszweck: It is indicated for use in combination with prednisone as a treatment for metastatic castration-resistant prostate cancer. Abiraterone is a drug used in combination with prednisone in metastatic castration-resistant prostate cancer (formerly hormone-resistant or hormone-refractory prostate cancer) — d.h., prostate cancer not responding to androgen deprivation or treatment with antiandrogens. It is formulated as the prodrug abiraterone acetate and …